Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging study of tofacitinib in active rheumatoid arthritis
NCT00687193Phase 2Completed
- Sponsor
- Pfizer
- Start
- Mar 2009
- Primary completion
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tofacitinib in rheumatoid arthritis (RA), sponsored by Pfizer. Primary endpoint: American College of Rheumatology 20% Response at 12 weeks. Started Mar 2009; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00687193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00687193.